OakChart

Apnimed Inc

APMDHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 2:06 PM ET

16.50+0.64 (4.04%)
2026-11-11 20:06 CET
Market cap
660.26 USD m
Revenue, TTM
12.08 USD m
Net income, TTM
125.94 USD m
Free cash flow, TTM
-18.11 USD m
EPS diluted, TTM
3.02
P/E
-
Compare

Price

APMD against its 20 and 50-day averages
2050beat
15.0020.0025.0030.0035.001.7M3.4MJul 26Sep 26Oct 26Nov 26APMDclose 16.5020-day 17.1050-day 20.9516.5052w high52w low

53.2% under the 52-week high of 35.29 on 18 Aug 2026. 52-week low 13.88 on 5 Nov 2026. Last 15 sessions, 42.9% high to low

Profile

APMD
52-week range, 12% of the way up
13.8835.29

Apnimed, Inc. operates as a clinical-stage company. It engages in the discovery, development, and commercialization of oral therapies for sleep-related breathing diseases. The company was founded by Lawrence G. Miller, Barry Wohl and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA.

IndexRUT
IPOJul 31, 2026
ATR, 14d1.67
Rel volume0.27
Short float5.08%
Insider own24.95%
Inst own38.12%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap686.90M
Enterprise Value840.39M
Income-
Sales-
Book/sh-4.23
Cash/sh4.15
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOJul 31, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C3.98
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.06
Current Ratio5.06
Debt/Eq1.15
LT Debt/Eq1.15
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-0.64
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-69.75% -
Sales past 3/5Y237.57% -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-
Sales Q/Q-
EarningsSep 08 AMC
EPS/Sales Surpr.905.42% -

Ownership

Insider Own24.95%
Insider Trans3.23%
Inst Own38.12%
Inst Trans32.17%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-3.52%
SMA50-21.26%
SMA200-28.81%
Trades-

Technical

Shs Outstand41.63M
Shs Float31.25M
Short Float5.08%
Short Ratio3.40
Short Interest1.59M
52W High35.29 -53.24%
52W Low13.88 18.88%
Volatility9.37% 9.18%
ATR (14)1.67
RSI (14)43.29
Beta-
Rel Volume0.27
Avg Volume466.91K
Volume91,531

Performance

Perf Week7.84%
Perf Month-7.46%
Perf Quarter-42.69%
Perf Half Y-
Perf YTD-25.00%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price50.33
Prev Close15.86
Price16.50
Change %4.04%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Aug 25, 2026InitiatedEEvercore ISIOutperform
Aug 25, 2026InitiatedCCantor FitzgeraldOverweight$60+263.6%
Aug 25, 2026InitiatedBBofA SecuritiesBuy$41+148.5%

Peers

Mkt cap
TickerCompanyMkt cap
IXHLIncannex Healthcare Inc25.83M
INSPInspire Medical Systems Inc1.78B
AXSMAxsome Therapeutics Inc7.81B
HRMYHarmony Biosciences Holdings Inc2.01B
JAZZJazz Pharmaceuticals plc15.82B
NYXHNyxoah SA91.93M
SVRASavara Inc1.13B
LLYLilly(Eli) & Co1345.11B
RMDResmed Inc33.07B
ALKSAlkermes plc7.94B

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Morningside Venture Investment10% OwnerAug 03 '26Buy16.00312,5005,000,0007,152,713Aug 05 04:18 PM
SEKHRI PAUL JDirectorAug 03 '26Buy16.0012,500200,00012,500Aug 03 04:01 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IWCiShares Micro-Cap ETFAUM: 1.22B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
SCHBSchwab U.S. Broad Market ETFAUM: 44.09B

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-083.920-0.4873.91012.080.003
2026Q12026-06-032.133-1.70184.87--
2026Q3---0.637--0.003
2026Q4---0.817--0.003
2027Q1---1.025--0.002
2027Q2---1.280--0.502
2027Q3---1.320--4.352
2027Q4---1.265--11.852

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-162000.000.000.00
2026Q3S2026-09-091000.000.000.00
2026Q3S2026-09-081000.000.000.00
2026Q3S2026-09-021000.000.000.00
2026Q3S2026-08-241000.000.000.00
2026Q3R2026-09-09100-0.71-0.71-0.71
2026Q3R2026-09-08100-0.71-0.71-0.71
2026Q3R2026-09-02100-0.71-0.71-0.71
2026Q3R2026-08-21100-0.71-0.71-0.71
2026Q3E2026-09-09301-0.64-0.71-0.59
2026Q3E2026-09-08300-0.63-0.71-0.58
2026Q3E2026-09-02300-0.63-0.71-0.58
2026Q3E2026-08-24300-0.63-0.71-0.58
2026Q3E2026-08-21100-0.71-0.71-0.71

Estimate history

EPS, annual-0.658-2.015-2.795-3.219
Period2022202320242025
EPS, quarterly-0.719-1.6691.7013.025
PeriodQ1 '25Q2 '25Q1 '26Q2 '26
Sales, annual108.01238.467
Period2022202320242025
Sales, quarterly3.13117.1184.81412.08
PeriodQ1 '25Q2 '25Q1 '26Q2 '26
Shares, annual39.82339.82339.82339.82341.631
Period2022202320242025MRQ
Shares, quarterly39.82341.63139.82341.631
PeriodQ1 '25Q2 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue12.0838.478.010.001.00
Cost of Goods Sold Incl. D&A1.216.693.370.00-
Gross Profit10.8731.774.64-0.00-
Selling, General and Administrative Excl. Other22.5785.59118.8848.5227.55
Research and Development9.9062.1097.3837.2120.92
Other Operating Expense0.000.000.000.000.00
Operating Income-11.70-53.82-114.23-48.52-26.55
Interest Expense--0.000.000.00
Unusual Expense2.925.650.000.000.00
Net Income Before Taxes126.11-58.05-108.55-42.75-26.21
Income Taxes0.000.000.050.000.00
Consolidated Net Income126.11-58.05-108.60-80.25-26.21
Net Income From Continuing Operations126.11-58.05-108.60-80.25-26.21
Net Income125.94-128.19-111.31-80.25-26.21
EPS (Recurring)3.09-3.12-2.79-2.02-0.66
EPS (Basic, Before Extraordinaries)3.02-3.22-2.79-2.02-0.66
EPS (Diluted)3.02-3.22-2.79-2.02-0.66
EBITDA-11.70-53.79-114.21-48.52-26.55
Non-Operating Income (Expense)140.731.415.685.770.34
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense1.193.912.401.560.99
Gross Margin-82.6057.95--
Operating Margin--139.91-1,425.79--2,654.80
Net Margin--333.25-1,389.23--2,620.80
Shares Outstanding41.6339.8239.8239.8239.82
Market Capitalization660.26660.26---

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Total Revenue12.0884.8117.113.13
Cost of Goods Sold Incl. D&A1.212.161.721.32
Gross Profit10.8782.6515.391.81
Selling, General and Administrative Excl. Other22.5714.6121.3228.93
Research and Development9.908.1015.9723.46
Other Operating Expense0.000.000.000.00
Operating Income-11.7068.04-5.94-27.11
Interest Expense---0.00
Unusual Expense2.92-2.110.000.00
Net Income Before Taxes126.1170.37-5.63-26.68
Income Taxes0.000.000.000.00
Consolidated Net Income126.1170.37-5.63-26.68
Net Income From Continuing Operations126.1170.37-5.63-26.68
Net Income125.9467.72-69.47-28.65
EPS (Recurring)3.091.66-1.67-0.72
EPS (Basic, Before Extraordinaries)3.021.70-1.67-0.72
EPS (Diluted)3.021.70-1.67-0.72
EBITDA-11.7068.05-5.93-27.11
Non-Operating Income (Expense)140.730.220.310.43
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense1.190.930.870.80
Gross Margin89.9897.4589.9257.94
Operating Margin-96.8980.23-34.69-865.92
Net Margin1,042.5179.84-406.04-914.92
Shares Outstanding41.6339.8241.6339.82
Market Capitalization660.26---

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments41.8968.35173.96133.83
Short Term Receivables0.961.110.000.00
Inventories0.000.000.000.00
Other Current Assets2.213.782.502.13
Total Current Assets45.0573.25176.46135.96
Net Property, Plant & Equipment0.901.160.050.00
Total Investments and Advances0.000.0037.500.00
Other Assets26.9234.820.030.03
Total Assets72.87109.22214.04135.99
Short Term Debt Incl. Current Port. of LT Debt0.250.220.000.11
Accounts Payable1.793.584.100.94
Other Current Liabilities108.8438.5516.092.42
Total Current Liabilities110.8842.3620.193.47
Long Term Debt41.270.870.000.00
Provision for Risks Charges0.000.000.000.00
Other Liabilities72.36109.72129.350.00
Total Liabilities224.51152.95149.543.47
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value221.15204.89204.89204.89
Common Equity-372.78-248.62-140.39-72.37
Total Shareholders Equity-151.64-43.7364.50132.52
Accumulated Minority Interest0.000.000.000.00
Total Equity-151.64-43.7364.50132.52
Total Liabilities & Stockholders Equity72.87109.22214.04135.99
Book Value Per Share-9.36-6.24-3.53-1.82
Tangible Book Value Per Share-9.36-6.24-3.53-1.82
Full-Time Employees--30-
Price to Book Ratio-3.75---
Return on Assets-63.76-67.19-45.85-
Return on Equity--1,045.65-81.46-
Return on Invested Capital---124.42-19.78
Quick Ratio0.411.738.7439.22
Current Ratio0.411.738.7439.22

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income125.94-128.19-111.31-80.25-26.21
Depreciation0.010.030.020.000.00
Other Funds (Non Cash)-78.3179.921.3135.061.18
Funds from Operations47.63-48.24-109.97-45.18-25.03
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital-65.75-29.59-0.2470.59-1.10
Cash from Operating Activities-18.11-77.83-110.2125.41-26.13
Capital Expenditures0.000.00-0.07-0.050.00
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments100.000.00152.03-143.310.00
Purchase of Investments0.000.00-146.97-270.310.00
Sale Or Maturity of Investments100.000.00299.00127.000.00
Other Uses-0.340.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities99.660.00151.96-143.350.00
Cash Dividends Paid0.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.00
Change in Capital Stock-0.9716.370.0510.66141.75
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock-0.9716.370.0510.66141.75
Proceedsfrom Stock Options-1.8316.260.0010.62141.75
Issuance or Reduction of Debt, Net45.3435.000.000.000.00
Change in Long Term Debt45.3435.000.000.000.00
Issuance of Long Term Debt48.1935.000.000.000.00
Reduction of Long Term Debt-2.850.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.00
Cash from Financing Activities44.3751.370.0510.66141.75
Exchange Rate Effect---0.000.00
Net Change in Cash125.92-26.4641.80-107.28115.62
Free Cash Flow-18.11-77.83-110.2825.36-26.13
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Cash & Short Term Investments172.8046.89--
Short Term Receivables0.690.88--
Inventories0.000.00--
Other Current Assets6.5026.70--
Total Current Assets179.9974.46--
Net Property, Plant & Equipment0.770.83--
Total Investments and Advances0.000.00--
Other Assets14.703.72--
Total Assets195.4679.02--
Short Term Debt Incl. Current Port. of LT Debt0.270.26--
Accounts Payable6.603.01--
Other Current Liabilities28.7137.72--
Total Current Liabilities35.5840.99--
Long Term Debt80.0839.09--
Provision for Risks Charges0.000.00--
Other Liabilities10.0457.12--
Total Liabilities125.70137.20--
Non-Equity Reserves0.000.00--
Preferred Stock - Carrying Value245.94245.94--
Common Equity-176.18-304.12--
Total Shareholders Equity69.76-58.18--
Accumulated Minority Interest0.000.00--
Total Equity69.76-58.18--
Total Liabilities & Stockholders Equity195.4679.02--
Book Value Per Share-4.23-7.64--
Tangible Book Value Per Share-4.23-7.64--
Full-Time Employees-65--
Price to Book Ratio-3.75---
Return on Invested Capital84.05---
Quick Ratio5.061.82--
Current Ratio5.061.82--

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Net Income125.9467.72-69.47-28.65
Depreciation0.010.010.010.01
Other Funds (Non Cash)-78.311.5364.772.82
Funds from Operations47.6369.26-4.70-25.82
Extraordinary Item0.000.000.000.00
Changes in Working Capital-65.75-89.07-12.67-2.63
Cash from Operating Activities-18.11-19.81-17.37-28.45
Capital Expenditures0.000.000.000.00
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00
Purchase or Sale of Investments100.000.000.000.00
Purchase of Investments0.000.000.000.00
Sale Or Maturity of Investments100.000.000.000.00
Other Uses-0.340.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities99.660.000.000.00
Cash Dividends Paid0.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.00
Change in Capital Stock-0.9724.8116.290.00
Repurchase of Common Pref Stock0.000.000.000.00
Sale of Common Pref Stock-0.9724.8116.290.00
Proceedsfrom Stock Options-1.8324.7916.260.00
Issuance or Reduction of Debt, Net45.340.000.000.00
Change in Long Term Debt45.340.000.000.00
Issuance of Long Term Debt48.190.000.000.00
Reduction of Long Term Debt-2.850.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00
Other Financing Activities Uses0.000.000.000.00
Cash from Financing Activities44.3724.8116.290.00
Net Change in Cash125.925.00-1.08-28.45
Free Cash Flow-18.11-19.81-17.37-28.45

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.08%1.6M31.3M508.31K
2026-10-155.77%1.8M31.3M539.24K
2026-09-304.55%1.8M38.8M556.10K
2026-09-152.27%0.9M38.8M454.66K
2026-08-311.46%0.6M38.8M535.97K
2026-08-141.05%0.4M38.8M692.64K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-04SCHEDULE 13GSEC
2026-09-08S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-0810-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-08-07SCHEDULE 13GSEC
2026-08-06SCHEDULE 13GSEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-07-30SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-07-30SEC
2026-08-034Statement of changes in beneficial ownership of securities2026-07-30SEC
2026-07-31S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-31424B4SEC
2026-07-30EFFECTEffectiveness filing by commission orderSEC
2026-07-30CERTSEC
2026-07-30S-1MEFA new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S-1SEC
2026-07-303Initial statement of beneficial ownership of securities2026-07-30SEC
2026-07-303Initial statement of beneficial ownership of securities2026-07-30SEC
2026-07-303Initial statement of beneficial ownership of securities2026-07-30SEC
2026-07-303Initial statement of beneficial ownership of securities2026-07-30SEC
2026-07-303Initial statement of beneficial ownership of securities2026-07-30SEC
2026-07-303Initial statement of beneficial ownership of securities2026-07-30SEC
2026-07-303Initial statement of beneficial ownership of securities2026-07-30SEC
2026-07-303Initial statement of beneficial ownership of securities2026-07-30SEC
2026-07-303Initial statement of beneficial ownership of securities2026-07-30SEC
2026-07-303Initial statement of beneficial ownership of securities2026-07-30SEC
2026-07-303Initial statement of beneficial ownership of securities2026-07-30SEC
2026-07-298-A12BSEC
2026-07-27S-1/ASEC
2026-07-10S-1General form of registration statement for all companies including face-amount certificate companiesSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-085.20M200
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Aberdeen Group plc2.27%
GEODE CAPITAL MANAGEMENT, LLC0.77%
FMR LLC0.67%
UBS Group AG0.44%
Bank of New York Mellon Corp0.06%
Nuveen, LLC0.04%
RHUMBLINE ADVISERS0.03%
DEUTSCHE BANK AG\0.03%
STRS OHIO0.01%
Police & Firemen`s Retirement System of New Jersey0.01%

Funds

Fund% owned
Columbia Seligman Technology and Information Fund17.30%
PGIM Jennison Health Sciences Fund1.17%
Select Biotechnology Portfolio0.22%
Multi-Manager Small Cap Equity Strategies Fund0.19%
Fidelity Nasdaq Composite Index Fund0.09%
Small Cap Value Fund0.04%
Franklin Alternative Strategies Fund0.03%
VANGUARD RUSSELL 2000 INDEX FUND0.02%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND0.00%
VANGUARD RUSSELL 2000 VALUE INDEX FUND0.00%

OakChart. APMD. Cached 15 minutes.

Some panels did not load: news.